Arginine- but not alanine-rich carboxy-termini trigger nuclear translocation of mutant keratin 10 in ichthyosis with confetti

Patricia Renz 1 | Elias Imahorn 1 | Iris Spoerri 1 | Magomet Aushev 2 | Oliver P. March 3 | Hedwig Wariwoda 1 | Sarah Von Arb 1 | Andreas Volz 4 | Peter H. Itin 1,4 | Julia Reichelt 3 | Bettina Burger 1

Abstract
Ichthyosis with confetti (IWC) is a genodermatosis associated with dominant-negative variants in keratin 10 (KRT10) or keratin 1 (KRT1). These frameshift variants result in extended aberrant proteins, localized to the nucleus rather than the cytoplasm. This mislocalization is thought to occur as a result of the altered carboxy (C)-terminus, from poly-glycine to either a poly-arginine or -alanine tail. Previous studies on the type of C-terminus and subcellular localization of the respective mutant protein are divergent. In order to fully elucidate the pathomechanism of IWC, a greater understanding is critical. This study aimed to establish the consequences for localization and intermediate filament formation of altered keratin 10 (K10) C-termini. To achieve this, plasmids expressing distinct KRT10 variants were generated. Sequences encoded all possible reading frames of the K10 C-terminus as well as a nonsense variant. A keratinocyte line was transfected with these plasmids. Additionally, gene editing was utilized to introduce frameshift variants in exon 6 and exon 7 at the endogenous KRT10 locus. Cellular localization of aberrant K10 was observed via immunofluorescence using various antibodies. In each setting, immunofluorescence analysis demonstrated aberrant nuclear localization of K10 featuring an arginine-rich C-terminus. However, this was not observed with K10 featuring an alanine-rich C-terminus. Instead, the protein displayed cytoplasmic localization, consistent with wild-type and truncated forms of K10. This study demonstrates that, of the various 3′ frameshift variants of KRT10, exclusively arginine-rich C-termini lead to nuclear localization of K10.

KEYWORDS
alanine-rich C-terminus, arginine-rich C-terminus, carboxy terminus, ichthyosis with confetti, keratin 10, KRT10, nuclear localization
1 | INTRODUCTION

Ichthyosis with confetti (IWC), also termed congenital reticular ichthyosiform erythroderma (CRIE) or ichthyosis variegata (OMIM #609165), is a keratinopathy associated with dominant-negative frameshift variants in keratin 10 (KRT10) and keratin 1 (KRT1). Skin of affected patients demonstrates generalized erythroderma, persisting throughout life. The disease is characterized by the appearance of numerous patches of pale, healthy-appearing skin in most patients during childhood. These increase in size and number with age. Currently, 57 patients from 40 families (49% male, 51% female) have been reported (Table 1). Of these, 50 were sequenced. The majority of these individuals (69%) display a heterozygous variant in KRT10 (familial 82%), whereas 31% carry a heterozygous variant in KRT1 (familial 18%).

Keratins comprise the components of the epithelial cytoskeleton. Acidic (type I) and basic (type II) keratins heterodimerize and subsequently assemble to form intermediate filaments (IFs). Epidermal keratinocytes specifically co-express keratins as pairs in a differentiation-dependent manner. Keratinocytes of the proliferative basal layer express keratin (K) 5 and K14. The differentiating suprabasal epidermal layers are associated with the down-regulation of K5/K14 and expression of thicker K1/K10 filament bundles.

All currently described IWC-associated variants are deletions, insertions or duplications located within the helix-termination-motif or in the V2 domain of either K10 or K1 (Table 1). Each results in frameshifts, leading to the translation of aberrant-truncated protein tails. Nonsense variants in the V2 domain of either K10 or K1 have not been reported. Variants leading to −2/+1 frameshifts within regions encoding the V2 domain are predicted to alter the downstream amino acid code from native glycine- to arginine-rich sequences. Arginine-rich sequences frequently function as nuclear localization signals. Therefore, aberrant arginine-rich K10 or K1 tails might be responsible for the pathogenic nuclear localization of K10 or K1, characteristic of IWC.

Two studies suggested that alanine-rich K10 tails might also lead to nuclear K10 localization. In contrast to arginine, alanine-rich sequences have not been described to function as nuclear localization signal. Lim et al. suggested that a KRT10 frameshift variant at the exon 6/intron 6 boundary resulted in an alanine-rich tail. However, the original c.1373delG nomenclature for this variant should rather be annotated as c.1373+1delG, according to the sequence variant nomenclature HGVS, indicating a splice site variant at the exon 6/intron 6 boundary. Variants of this nature often lead to the expression of multiple splicing products. Full examination of the expression products of this variant is therefore justified. The presence of additional K10 splicing products, featuring arginine-rich tails, may explain the nuclear K10 localization displayed in the epidermis of this patient. Horst et al. also suggested that an IWC-associated variant (c.1544delG) resulted in an alanine-rich K10 tail. However, the variant was later on corrected to c.1544dupG and has been suggested to result in an arginine-rich K10 tail.

In support of a non-nuclear localizing signal of alanine-rich keratin tails, frameshift variants in KRT1, leading to alanine-rich tails, are reported to cause ichthyosis hystrix Curth-Macklin (IHCMe) and striate palmoplantar keratoderm (SPPK). Keratinocytes of these patients do not display nuclear localization of aberrant K1 products.

The aim of this study was to clarify the effects of mutant K10 tail variants on the pathogenic nuclear localization of the protein. In order to elucidate this, we established two distinct cell culture models. The first model (transgenic model) centred on the transient expression of N-terminal eGFP-labelled K10 cDNA or gDNA, featuring mutant K10 tail variations, in an immortalized wild-type human keratinocyte line (NKC21). This model enabled determination of the subcellular localization of K10 translated from IWC-associated alleles. In vivo, the effects of KRT10 variants are not observable in undifferentiated keratinocytes. Endogenous regulation of KRT10 expression ensures equal ratios of mutant and wild-type K10. Therefore, a context more closely resembling the in vivo situation enabled better analysis of the effect of IWC-associated alleles. This was achieved through the second model (endogenous model), generated via CRISPR/Cas9-mediated gene editing, which featured these variants at the endogenous KRT10 locus in NKC21 keratinocytes.

This study elucidates the relationship between K10 C-termini variants and K10 nuclear localization. The influence of C-termini variants on keratinocyte differentiation, K10 polymerization with assembly partners and the intracellular localization of these polymers were additionally characterized.

2 | MATERIAL AND METHODS

2.1 | Plasmids and transfection
cDNA-derived KRT10 was PCR-generated from epidermal mRNA isolated from an IWC patient$^5$ (p5_arg_c_GFP) or a healthy control (p2_wt_c_GFP). This was cloned into XhoI and HindIII sites of the pEGFP-C1 vector (Clontech Laboratories Inc Takara). Sequences encoding the alanine-rich C-terminus (p10_ala_c_GFP) or a premature stop (p13_ter_c_GFP) were inserted into p2_wt_c_GFP via site-directed mutagenesis (GenScript$^6$). Genomic DNA-derived KRT10 from a healthy control was cloned into pUC19 in two steps following amplification of KRT10 as 3′ and 5′ products. Initially, intron 5 to 3′-UTR gDNA was inserted into the HincII and HindIII restriction sites of pUC19 (pUC_K10-ex5-3′). Subsequently, the 5′ product (mid of exon 1 to exon 4) was introduced into the SacI and HindIII restriction sites of pUC_K10-ex5-3′. This combined product (pUC_K10) was inserted into the SacI and HindIII restriction sites of p2_wt_c_GFP, exchanging cDNA between mid of exon 1 to 3′-UTR for a complete gDNA sequence. This wild-type gDNA construct (p1_wt_g_GFP) contained a common 12 bp deletion in exon 7 (rs786613907$^7$) enabling it to be distinguished from endogenous KRT10 of NKC21. The IWC100 variant$^{10}$ (c.1373+1delG) (p4_var_g_GFP) was inserted via site-directed mutagenesis (GenScript$^6$). Subconfluent NKC21 keratinocytes were transfected with p1_wt_g_GFP or p4_var_g_GFP to receive the differentially spliced KRT10 mRNA. After full-length PCR and separation on 1% agarose gel, they were cloned into pEGFP-C1

3 | MATERIALS AND METHODS

3.1 | Plasmids and transfection
cDNA-derived KRT10 was PCR-generated from epidermal mRNA isolated from an IWC patient$^5$ (p5_arg_c_GFP) or a healthy control (p2_wt_c_GFP). This was cloned into XhoI and HindIII sites of the pEGFP-C1 vector (Clontech Laboratories Inc Takara). Sequences encoding the alanine-rich C-terminus (p10_ala_c_GFP) or a premature stop (p13_ter_c_GFP) were inserted into p2_wt_c_GFP via site-directed mutagenesis (GenScript$^6$). Genomic DNA-derived KRT10 from a healthy control was cloned into pUC19 in two steps following amplification of KRT10 as 3′ and 5′ products. Initially, intron 5 to 3′-UTR gDNA was inserted into the HincII and HindIII restriction sites of pUC19 (pUC_K10-ex5-3′). Subsequently, the 5′ product (mid of exon 1 to exon 4) was introduced into the SacI and HindIII restriction sites of pUC_K10-ex5-3′. This combined product (pUC_K10) was inserted into the SacI and HindIII restriction sites of p2_wt_c_GFP, exchanging cDNA between mid of exon 1 to 3′-UTR for a complete gDNA sequence. This wild-type gDNA construct (p1_wt_g_GFP) contained a common 12 bp deletion in exon 7 (rs786613907$^7$) enabling it to be distinguished from endogenous KRT10 of NKC21. The IWC100 variant$^{10}$ (c.1373+1delG) (p4_var_g_GFP) was inserted via site-directed mutagenesis (GenScript$^6$). Subconfluent NKC21 keratinocytes were transfected with p1_wt_g_GFP or p4_var_g_GFP to receive the differentially spliced KRT10 mRNA. After full-length PCR and separation on 1% agarose gel, they were cloned into pEGFP-C1
# TABLE 1 Overview of reported patients with IWC

| No of patients | No of families | Sex | Male | Female | Clinically described | Without spots | Affected gene | KRT1 | KRT10 | Type of variant | Reference |
|----------------|---------------|-----|------|--------|----------------------|---------------|--------------|------|-------|----------------|-----------|
| 1*            | 1             | 1   | 1    |        |                      |               |              |      |       | Unknown         | 4         |
| 1*            | 1             | 1   | 1    |        |                      |               |              |      |       | Unknown         | 30        |
| 1*            | 1             | 1   | 1    |        |                      |               |              |      |       | Unknown         | 31        |
| 1*            | 1             | 1   | 1    |        |                      |               |              |      |       | Unknown         | 32        |
| 1*            | 1             | 1   | 1    |        |                      |               |              |      |       | Unknown         | 33        |
| 1*            | 1             | 1   | 1    |        |                      |               |              |      |       | Unknown         | 34        |
| 6             | 6             | 3   | 3    | 3      |                      |               |              |      |       |                |           |
| 1             | 1             | 1   | 1    |        |                      |               |              |      |       | c.1370G>T†     | 1.35      |
| 1             | 1             | 1   | 1    |        |                      |               |              |      |       | c.1373+1delG†† | 10        |
| 3             | 1             | 2   | 1    |        |                      |               |              |      |       | c.1373+1G>A    | 1         |
| 3             | 1             | 1   | 2    | 3      |                      |               |              |      |       | c.1373+2T>C    | 14        |
| 1             | 1             | 1   | 1    |        |                      |               |              |      |       | c.1374-2delA   | 1         |
| 1             | 1             | 1   | 1    | 1      |                      |               |              |      |       | c.1374-2A>C    | 36        |
| 2             | 2             | 2   | 1    |        |                      |               |              |      |       | c.1374-2A>G    | 1.37      |
| 4             | 3             | 1   | 2    | 2      |                      |               |              |      |       | c.1374-1G>A    | 1.5,38    |
| 5             | 5             | 3   | 3    | 6      | 1                    |               |              |      |       | c.1374-1G>C    | 5,14,39-41|
| 1             | 1             | 1   | 1    |        |                      |               |              |      |       | c.1383_1414del | 39        |
| 1             | 1             | 1   | 1    |        |                      |               |              |      |       | c.1411_1412insA| 14        |
| 1             | 1             | 1   | 1    |        |                      |               |              |      |       | c.1449_1450insC| 1         |
| 1             | 1             | 1   | 1    |        |                      |               |              |      |       | c.1452_1444delinsAG| 42 |
| 1             | 1             | 1   | 1    |        |                      |               |              |      |       | c.1506_1507del  | 1         |
| 2             | 2             | 2   | 2    |        |                      |               |              |      |       | c.1544dupG‡    | 1.14      |
| 1             | 1             | 1   | 1    |        |                      |               |              |      |       | c.1546_1551delinsT| 3.5,45 |
| 1             | 1             | 1   | 1    |        |                      |               |              |      |       | c.1557_1558delIG| 5         |
| 2             | 1             | 1   | 1    |        |                      |               |              |      |       | c.1560_1561delIG| 1         |
| 2             | 1             | 2   | 1    |        |                      |               |              |      |       | c.1573dupA      | 5         |
| 35 (69%)      | 28 (82%)      | 15  | 20   | 25      | 4                    | 20            | 43% exonic, 57% splice site | (families) |          |                   |           |
| 6             | 1             | 2   | 4    | 5      | 3a                   | c.591+329_1129-37del| 46 |
| 1             | 1             | 1   | 1    |        | 1b                   | c.1756_1757insG††| 47 |
| 1             | 1             | 1   | 1    |        | 1b                   | c.1752dupT     | 14 |
| 3             | 1             | 1   | 2    | 3      | 1                   | c.1758_1759insT| 48 |
| 1             | 1             | 1   | 1    |        | 1c                   | c.1860_1861insT| 49 |
| 4             | 1             | 4   | 4    |        | c.1865_1866insG      | 2            |
| 16 (31%)      | 6 (18%)       | 10  | 6    | 15      | 7                   | 6             | 100% exonic |            |          |                   |           |

Note: All IWC patients carry heterozygous variants in KRT10 (NM_000421) or KRT1 (NM_006121). Two variants, originally described as a poly-alanine reading frame, have been redefined according to HGVS nomenclature (indicated by †† and ‡). Six patients, which have not been sequenced but displayed typical IWC clinical features, including pale spots, are also listed (indicated by *). Data include eleven patients from different families who have not currently developed pale spots but carry a poly-arginine tail-causing frameshift variant. Of these, three siblings in a familial IWC resembled epidermolytic ichthyosis (EI) (indicated by a). Three sporadic cases were clinically described as EI (indicated by b) or ichthyosis hystrix Curth-Macklin (IHCM) (indicated by c).  

a Resembled epidermolytic ichthyosis (EI).  
b Described as epidermolytic hyperkeratosis, renamed as epidermolytic ichthyosis (EI) (OMIM #113800).  
c Described as ichthyosis hystrix Curth-Macklin (OMIM #146590).  
† Originally described as c.1369G>T; results in a new donor splice site.  
†† Originally described as c.1373delG (alanine-rich C-terminus).  
††† Originally described as c.1751insG.  
‡ One of them initially described as c.1544delG (alanine-rich C-terminus).
using XhoI and HindIII restriction sites (Figure 1A). To distinguish the KRT10wt, KRT10arg and KRT10ala products following combined transfection in cell imaging analyses, eGFP in p6_arg_s_GFP and p11_ala_s_GFP was replaced with mCherry. Constructs are summarized in Table S1 and Figure S1. NKc21 keratinocytes were transfected with Xfect transfection reagent (Takara Bio Europe) as previously described.18 Transfected cells were seeded on coverslips 48 hours post-treatment and subsequently fixed 24 hours later with 4% formaldehyde. Transfection rates were approximately 30%.

2.2 | Cell culture

Keratinocyte line NKc21 (kindly provided by Hans Törmä)19 was grown in CnT-PR (CELLnTEC). Cells were cultured in a humid atmosphere at 37°C and 5% CO2. Integrity of cells and chromosomes was validated by SNP array (Illumina, HumanOmniExpressExome-8v1-3).

Mouse 3T3-J2 fibroblasts (ATCC) were grown in DMEM (Lonza) supplemented with antibiotic-antimycotic and 10% foetal calf serum (ThermoFisher Scientific Inc). Feeder cells were generated from this cell line following mitomycin C (StressMarq Biosciences) treatment (4 mg/mL for 2 hours). These were subsequently used in keratinocyte single-cell cloning.

2.3 | CRISPR-Cas9-mediated gene editing and single-cell cloning

Plasmid pSpCas9(BB)-2A-GFP (PX458) (kindly gifted from Feng Zhang, Addgene plasmid #48138) was used for generation of GFP-labelled Cas9 vectors.20 In brief, the sgRNA oligos were ligated into pSpCas9(BB)-2A-GFP after digestion with restriction enzyme BbsI. These resulted vectors carried either guide RNA cr26 (GGCGGGCGAAAGTTTGGCGG, KRT10, exon 7) or cr33 (GGCGGGCGAAAGTTTGGCGG, KRT10, exon 6). Plasmids were transfected with Xfect polymer (Takara Bio) as previously described.18 Briefly, 70 000 keratinocytes per well were seeded in 6-well plates. One day later, a mixture of 660 ng of CRISPR/Cas9 plasmid, 0.2 µL Xfect polymer and 100 µL Xfect buffer was incubated at room temperature for 10 minutes and added to the keratinocytes. After 4 hours at 37°C, the medium was exchanged. Individual GFP-fluorescent cells were FACSorted 72 hours later on an Aria II cell sorter (BD Biosciences) using 100 µm nozzle and 15 psi pressure. They were co-cultivated with mouse 3T3-J2 feeder fibroblasts (ATCC)21 previously arrested with 4 g L-1 mitomycin C (StressMarq Biosciences) in 96-well plates. Clones were subsequently expanded. Corresponding sequence data on KRT10 are summarized in Table S2.

2.4 | Keratinocyte differentiation and epidermal equivalent formation

Since KRT10 is only expressed in differentiated cells, differentiation was induced in confluent cultures in the absence of growth factors and at high calcium concentration (1.2 mM). For mRNA isolation, keratinocytes were cultured in CnT-PR medium (CELLnTEC). One day before expected confluency, medium was exchanged to CnT-PR-D (CELLnTEC). At confluency, CaCl2 (Vitaris) was added to a final concentration of 1.2 mM. RNA was isolated 72 hours after addition of calcium.

For cellular localization of K10, clonal keratinocyte cultures were seeded onto 0.4 µm PCF Millicell cell culture inserts (Merck Millipore) and cultured in CnT-PR medium. After 3 days, cells reached confluency and the medium was exchanged with CnT-PR-3D (CELLnTEC) to promote differentiation. The following day, medium inside the insert was removed. Medium outside the insert was changed three times a week. Two weeks after the start of differentiation, epidermal models were formalin-fixed and paraffin-embedded (FFPE) for subsequent haematoxylin and eosin staining. Each frameshift mutation was analysed with two distinct clones. For K10arg six differentiated clones (2x e3_arg_26-1, 4x e4_arg_26-1) and for K10ala nine differentiated clones (6x e5_ala_26-1, 3x e6_ala_26-1) were examined.

For quantitation of epidermal thickness, the thickness of keratinocyte layers and insert membrane was measured on haematoxylin- and eosin-stained epidermal equivalents. For K10arg six differentiated clones (2x e3_arg_26-1, 4x e4_arg_26-1) and for K10ala seven differentiated clones (4x e5_ala_26-1, 3x e6_ala_26-1) were examined. ANOVA tests were used for statistical analysis.

2.5 | Sequencing of gDNA and RNA

Genomic DNA and mRNA were isolated from confluent keratinocyte cultures 48 hours post-transfection according to the manufacturer’s protocol (NucleoSpin® Tissue and NucleoSpin® RNA XS, Macherey-Nagel). cDNA was synthesized (Verso cDNA Synthesis kit, ThermoFisher Scientific Inc) and amplified by PCR with KRT10-specific primers (Taq DNA or HotStar HiFidelity polymerase, Qiagen) (Table S3). Sanger sequencing was performed by an external vendor (Microsynth AG).

2.6 | Ratio of mRNA p9_arg_s_GFP and p11_ala_s_GFP

AB 3130 Genetic Analyzer was used to determine the ratio of KRT10arg (p9_arg_s_GFP) and KRT10ala (p11_ala_s_GFP) mRNA within PCR products (Figure 1) by fragment analysis as previously described.22 In brief, PCR was performed on cDNA following p4_var_g_GFP transfection with one FAM-labelled primer. This was stopped after 30 cycles to stay in the log phase of amplification. GeneScan™ 500 ROX™ (ThermoFisher Scientific Inc) was used as size standard. Quantitative assessment of PCR product was achieved following calculation of areas under the curve using GeneMapper.

2.7 | Immunofluorescence staining

Immunofluorescence staining was performed as previously described both on keratinocytes containing the respective plasmid grown on coverslips and on formalin-fixed and paraffin-embedded (FFPE-slides) keratinocytes of the epidermal models.3
In brief, samples were blocked in donkey serum and Triton-X-100 in TBS for 1 hour and incubated with primary antibodies either at RT for 1 hour (coverslips) or at 4°C overnight (slides). After washing, secondary antibody and DAPI for nuclear staining (Sigma-Aldrich) were incubated at RT for 1 hour. After additional washing steps, samples were mounted with ProLong™ Diamond Antifade Mountant (ThermoFisher Scientific Inc). The following primary antibodies were used: mouse monoclonal antibodies to the N-terminus of K10 DE-K10 (Abcam) and LH2 (kindly gifted by Irene Leigh, Dundee, UK, and Andrew South, Philadelphia, USA), rabbit monoclonal antibodies to the carboxy terminus of K10 SP99 and EP1607IHCY (both Abcam) (Table S4). Additional primary antibodies were goat polyclonal to GFP (Abcam), rabbit polyclonal to K5 (Biolegend) and monoclonal to K14 (EP1612Y, Abcam) as well as polyclonal rabbit to lamin B1 and fibrillarin (both Abcam). Conjugated secondary donkey antibodies originated from Jackson ImmunoResearch and ThermoFisher Scientific Inc fluorescent signals were imaged under a Zeiss confocal microscope LSM710 with a Zeiss 40x/1.3 and 63x/1.4 objective.

3 | RESULTS

3.1 | IWC-associated KRT10 variants result in an arginine-rich C-terminus

NKc21 keratinocytes were transfected with KRT10 gDNA constructs, featuring either wild-type (p1_wt_g_GFP) or a previously described IWC-associated splice site variant (p4_var_g_GFP)10 to investigate the presence and composition of potential additional splice products (Table S1). The wild-type construct resulted in the transcription of one main mRNA product of the expected size (2.1 kb) (wt_s). In contrast, the construct encoding the IWC-causing sequence resulted in four major products, of differing sizes (~2.4, ~2.1, ~1.9 and ~1.8 kb). Each product was cloned into pEGFP-C1 for further studies. B. Unsaturated PCR following RT-PCR of transcripts after transfection with p4_var_g_GFP, using primers localized in exon 6 and 7. These only amplify the 2.1 kb products. Separation of the resulting products (3130x Genetic Analyzer, Applied Biosystems) showed peaks at 272 bp (arg_s) and 276 bp (ala_s). Measurement of the area under the curve (ht) revealed the quantity of PCR product, almost double the amount of the 4 bp shorter KRT10 (arg_s, r.1369_1373del) vs. KRT10 (ala_s, r.1373del) PCR product. Red triangles indicate the size marker (GeneScan™ 500 ROX™ (ThermoFisher Scientific Inc)).
p14_ter_s_GFP) contained the complete intron 6, resulting in a shifted reading frame with a stop codon after 4 bp of intron 6. The fourth product contained two sequences, with the majority of products displaying a 5 bp deletion of the 3′-terminus of exon 6 (r.1369_1373del, p.Gly457PhefsTer118; subcloned in p9_arg_s_GFP) leading to K10 arg expression. A minority of products displayed a deletion of the last nucleotide of exon 6 (r.1373del; subcloned in p11_ala_s_GFP), encoding K10 asp (p.Ser458AsfsTer157). Quantitative assessment of an unsaturated PCR enabled relative PCR quantification and revealed 66% KRT10 arg (p9_arg_s_GFP) and 33% KRT10 asp (p11_ala_s_GFP) products (Figure 1B).

In summary, the majority of identified mRNAs resulting from p4_var_g_GFP encoded an aberrant K10 arg (p6_arg_s_GFP, p8_arg_s_GFP, p9_arg_s_GFP). The remainder encoded either K10 ter (p14_ter_s_GFP) or K10 asp (p11_ala_s_GFP). This indicates that a change in the donor splice site of intron 6, due to the 1 bp deletion, results in alternative splicing and frequently arginine-rich C-termini. Alternative splicing is supported by splice site prediction tools such as BDGP (0.93 → below cut-off 0.40; http://www.fruitfly.org/seq_tools/splice.html), NetGene2 (0.93 → 0.71; http://www.cbs.dtu.dk/services/NetGene2/) and SplicePort (1.06 → not recognized; http://spliceport.ccb.org/). These suggested a reduced confidence for the recognition of the mutated splice site compared with the wild-type sequence.

### 3.2 | Nuclear translocation of K10 is initiated by an arginine-rich C-terminus

The consequence of IWC-associated KRT10 variants on cellular localization was initially analysed in vitro. Plasmids encoding eGFP-labelled KRT10 cDNA were generated. These carried previously reported IWC-associated frameshift variants described to result in each alternate reading frame (-2/+1 or -1/+2). Transient expression in keratinocytes resulted in arginine- (K10 arg) and alanine-rich (K10 asp) K10 products, respectively. Additionally, keratinocytes transiently expressing a cDNA featuring a hypothetical nonsense variant localized to the region encoding the V2 domain of K103-11. This was observed (Figure S3). Alternatively, the plasmids carried a splice product expressed by Nk21 cells after transfection with p4_var_g_GFP (Table S1). Plasmids expressing these eGFP-tagged KRT10 cDNA variants (p2 WT_c_GFP, p5_arg_c_GFP, p10_ala_c_GFP, p13_ter_c_GFP) in addition to gDNA (p1 WT_g_GFP, p4_var_g_GFP) and previously subcloned splice products (p3 WT_s_GFP, p6 arg_s_GFP, p8 arg_s_GFP, p9 arg_s_GFP, p11_ala_s_GFP, p14_ter_s_GFP) were transiently transfected into Nk21 cells. This enabled analysis of the subcellular localization of each aberrant K10 product. Wild-type K10 (K10 WT) encoded by p1 WT_g_GFP, p2 WT_c_GFP and p3 WT_s_GFP was exclusively observed in the cytoplasm. Here, it was organized into filament structures (Figure 2). K10 arg from patient-derived cDNA (p5 arg_c_GFP), K10 arg-expressing plasmids (p6 arg_s_GFP, p9 arg_s_GFP) and products translated from IWC-related sequence (p4 var_g_GFP) displayed nuclear localization (Figure 3). K10 asp (p10_ala_c_GFP, p11_ala_s_GFP) and truncated K10 ter (p13 ter_c_GFP, p14 ter_s_GFP) were exclusively localized to the cytoplasm (Figure 4). As expected, aberrant K10 could not be detected via C-terminus-specific antibodies (EP16071HCY, SP99) (Figure S2).

Co-transfection with combinations of distinct fluorescence-labelled KRT10 arg and KRT10 asp (p6 arg_s_GFP/p12_ala_s_mCherry or p7 arg_s_mCherry/p11_ala_s_GFP) resulted in an expected nuclear signal of K10 arg. However, the unexpected nuclear localization of K10 asp was also observed (Figure S3). Co-transfection with distinct fluorescence-labelled K10 arg (p7 arg_mCherry) and K10 WT (p3 WT_s_GFP) resulted in nuclear-localized eGFP. This indicated co-translocation of K10 WT with K10 arg into the nucleus. Further, it may suggest the nuclear translocation of higher keratin polymers (Figure S3).

Immunostaining of cellular K5 and K14 after Nk21 transfection with a K10 arg vector (p5 arg_c_GFP) revealed a nuclear signal for endogenous K5 in approximately 30% of all transfected cells (Figure S4). K5 is a type II keratin, a promiscuous assembly partner of the type I K10. The apparent nuclear signal of K5 suggests the co-transport of keratin dimers. A nuclear K14 signal was not detectable (data not shown).

Our results indicate that exclusively aberrant K10 arg is translocated to the nucleus. Furthermore, they suggest that aberrant K10 arg can pull other keratins (ie K10 WT, K10 asp, and K5), which do not feature an arginine-rich C-terminus, into the nucleus. This likely occurs as keratin dimers and tetramers.

### 3.3 | Endogenous expression of aberrant K10 leads to abnormal differentiation of keratinocytes in culture

Keratinocyte clones were generated via CRISPR/Cas9-mediated gene editing enabling the introduction of heterozygous -2/+1 (KRT10 arg) or -1/+2 (KRT10 asp) frameshifts into regions encoding the V2 domain. As a result, variants similar to those found in IWC patients were generated in Nk21 keratinocytes. This enabled the analysis of aberrant K10 subcellular localization in an endogenous setting. Six clones with heterozygous frameshift variants were studied. Four displayed expression K10 arg (e1 arg_33-1, e2 arg_33-1, e3 arg_26-1, e4 arg_26-1), and two demonstrated expression K10 asp (e5 asp_26-1, e6 asp_26-1) (Table S2). Sequencing of cDNA derived from differentiated cells confirmed transcription of the expected KRT10 mRNAs (Table S2).

Epidermal equivalents derived from K10 arg single-cell clones were subjected to haematoxylin and eosin (HE) staining. These displayed stratified epithelium including: basal layer, differentiated suprabasal layers and stratum corneum comparable to wild-type and mock controls (Figure 5A-C). However, epidermal equivalents derived from K10 asp clones displayed an epithelium with strongly impaired differentiation and significantly thinner than epidermal equivalents from K10 arg and K10 WT (Figure 5D, Figure S5).

Immunofluorescence analysis of differentiated keratinocytes via either N- or C-terminus-specific anti-K10 antibodies indicated
4 | DISCUSSION

In keratinocytes derived from IWC patients, K10 displays nuclear localization, correlated with −2/+1 frameshift variants (K10\textsubscript{arg}). However, the effect of K10\textsubscript{ala} was previously inconclusive. Approximately 70% of IWC patients carry KRT10\textsubscript{frameshift} variants. These affect splice sites in 60% of cases. Of the currently reported IWC-associated KRT10 splice site variants, approximately 30% affect the donor splice site of intron 6. Analysis of mRNA from patients with IWC-associated splice site variants revealed transcripts that would be translated into K10 with arginine-rich tails.\textsuperscript{3} Lim et al\textsuperscript{10} described a K10 splice site variant, comprised of a 1 bp deletion at the exon-intron boundary of exon 6/IVS6. They suggested that this variant resulted in K10\textsubscript{ala} expression, without experimental confirmation.\textsuperscript{10} In the present study, we demonstrated that this variant leads to several alternative splicing products. In contrast to prior suggestions, the majority of these products are predicted to result in K10\textsubscript{arg} expression.

C-terminal frameshift variants in KRT10 remain poorly investigated in a systematic manner. Therefore, little is understood regarding the effects of IWC-associated variants on the cellular localization of K10. Our studies provide the first systematic analysis on nuclear K10 localization in IWC. Three possible C-terminal frames of KRT10 were analysed in addition to a speculative nonsense variant. Our data clearly indicate that only K10\textsubscript{arg} translocates to the nucleus, whereas K10\textsubscript{ala} and K10\textsubscript{ter} remain in the cytoplasm. However, the presence of K10\textsubscript{arg} enables the co-translocation of non-K10\textsubscript{arg} into the nucleus.

These results contradict a previous suggestion that K10\textsubscript{ala} may cause pathogenicity in an IWC patient with a splice site variant.\textsuperscript{10} However, sequencing of the corresponding cDNA was not previously performed to confirm a frameshift at the level of transcription. Human splice sites are highly conserved; >99.9% are canonical (donor site: GT, GC, AT).\textsuperscript{23} Further, exonic sequences close to the exon-intron boundaries are highly conserved. The 3′-most exonic nucleotide is a guanine in over 80% of instances.\textsuperscript{24-26} Analysis of splicing products from gDNA harbouring this variant revealed five transcripts. Three of these encoded K10\textsubscript{arg}, one encoded K10\textsubscript{ter}, and a minor transcript encoded K10\textsubscript{ala} at the limit of detection. The presence of these transcript varieties concurs with splice site prediction tools. However, a similar in vivo splicing profile could only be confirmed in patient epidermal biopsies.

In addition to the patient described by Lim et al\textsuperscript{10} three families reportedly carry similar variants with exchanges in the splice site sequence (c.1373+1G>A; c.1373+1G>C; c.1373+2T>C).\textsuperscript{111} mRNA isolated from a patient carrying the c.1373+1G>A variant displayed a full deletion of exon 6,\textsuperscript{11} a product identical to a major splice product that we observed (p6\_arg\_s). This patient data support our findings that splicing of this mutant mRNA frequently causes deletion of exon 6. This results in frameshift and consequently K10\textsubscript{arg} expression.
In K10\textsubscript{ala}, altered C-terminal amino acids result in the loss of neutral glycine loops in favour of neutral alanine sequences. Basic amino acids, associated with classical nuclear localization sequences, are not present. As a result, K10\textsubscript{ala} is not expected to display an altered subcellular localization. In contrast, the basic amino acid arginine is assumed to change the pK-value of the C-terminus of K10\textsubscript{arg} and subsequently the recognition signal for nuclear targeting.  

The endogenous model, described in the present study, supported a cytoplasmic localization of K10\textsubscript{ala}. Epidermal equivalents grown from keratinocytes expressing K10\textsubscript{ala} demonstrated significantly impaired stratification. In contrast to K1, in which
FIGURE 5  Epidermal equivalents derived from gene edited NKc21 single-cell clones expressing K10_{ala} displayed thin epithelium. Haematoxylin and eosin staining of epidermal models. Epidermal equivalents derived from wild-type (A), mock control (B), and heterozygous K10_{arg} clones (C) displayed a differentiated epithelium including basal layer and stratum spinosum (orange bar). Epidermal equivalents derived from K10_{ala} clones demonstrated a thin epithelium (D). All shown clones were cultivated in parallel, epidermal equivalents C and D are derived from clones e4_{arg}_26-1 (K10_{arg}) and e6_{ala}_26-1 (K10_{ala}). Parakeratosis was observed in all samples (black arrows). The supporting filter membrane is indicated (green bar). Scale bar (black), 20 μm.

FIGURE 6  Epidermal equivalents derived from K10_{arg} keratinocyte single-cell clones display nuclear localization of K10 in differentiated suprabasal layers. Immunofluorescence staining via N- (LH2, exact binding region unknown; red) and C-terminus-specific (EP1607IHCY, amino acids 555-584; green) K10 antibodies indicated nuclear localization of K10 in the suprabasal keratinocytes of K10_{arg}-derived equivalents (white arrowhead). In K10_{wt} or K10_{ala}-derived equivalents, K10 was localized exclusively in the cytoplasm. Nuclear co-translocation of endogenous K10_{wt} and K10_{arg} (e4_{arg}_26-1) enabled observation of nuclear localization via the C-terminus-specific anti-K10 (white arrowhead). DAPI (blue) was used for nuclear staining. Border between supporting filter membrane and basal layer indicated (white-dotted line). Scale bar, 20 μm.
an alanine-rich C-terminus results in the severe phenotype of IHCMI,15,16,29 or SPPK,17 no patients have been described with K10ala-associated variants. This is in line with our data of an impaired differentiation in K10ala keratinocytes, which might result in lethality.

Keratins promiscuously form heterodimers consisting of equimolar amounts of type I and type II keratins.3 They subsequently polymerize to form keratin IFs. K1 is present within the nucleus of K10arg-positive keratinocytes of IWC patients.1 This is likely co-translocated with K10arg in the form of dimers. In line with this observation, we observed nuclear co-localization of K5 with K10arg in our model systems. This has also been observed in patient keratinocytes (unpublished data). Further, we observed nuclear co-localization of K10arg/K10wt in addition to K10arg/K10ala. This may be a result of K10arg-containing tetramers or higher-order polymers passing the nuclear membrane. However, K14 was unexpectedly not detectable in the nuclear keratin complexes, possibly a result of poor epitope recognition by the monoclonal antibody.

In summary, this study provides a deeper understanding of the nuclear localization of aberrant K10 in IWC which is correlated to a single altered reading frame in K10. We confirmed that arginine-rich K10 tails, and not alanine-rich K10 tails, are responsible for the pathogenic nuclear localization of K10 in affected patients. A greater understanding of keratin nuclear localization in IWC advances the potential use of the subsequent mechanism of chromosomal exchange for natural gene therapies.

ACKNOWLEDGEMENTS

We thank Hans Törmä (Uppsala, Sweden) for providing the NKc21 cell line and Irene Leigh and Andrew South for providing the antibody LH2. We are grateful to our Pathology Department for embedding the epidermal equivalents and Nicholas Sanderson (Basel, Switzerland) for support in cloning. We also thank our microscope and FACS facilities for support. The study was ethically approved by the local ethics committee (Ethikkommission Nordwest- und Zentralschweiz) (EK203/13) and financially supported by Louis Widmer Fonds (Schlieren, Switzerland).

CONFLICT OF INTEREST

Nothing to disclose.

AUTHOR CONTRIBUTIONS

PR, EI, IS, HW and SvA performed the experiments. MA, OPM and AV contributed essential tools. PR, AV and BB analysed the data. BB, JR and OPM wrote the paper. PHI, JR and BB designed the study.

DATA AVAILABILITY STATEMENT

I am willing to share my research data.

REFERENCES

1. Choate KA, Lu Y, Zhou J, et al. Mitotic recombination in patients with ichthyosis causes reversion of dominant mutations in KRT10. Science. 2010;330(6000):94–97.
2. Choate KA, Lu Y, Zhou J, et al. Frequent somatic reversion of KRT1 mutations in ichthyosis with confetti. J Clin Invest. 2015;125:1703–1707.
3. Burger B, Spoerri I, Schubert M, et al. Description of the natural course and clinical manifestations of ichthyosis with confetti caused by a novel KRT10 mutation. Br J Dermatol. 2012;166:434–439.
4. Camenzind M, Harms M, Chavaz P, Saurat JH. [Confetti ichthyosis]. Ann Dermatol Venereol. 1984;111:675–676.
5. Spoerri I, Brena M, De Mesmaeker J, et al. The phenotypic and genotypic spectra of ichthyosis with confetti plus novel genetic variation in the 3′ end of KRT10: from disease to a syndrome. JAMA Dermatol. 2015;151:64–69.
6. Hatzfeld M, Franke WW. Pair formation and promiscuity of cytokeratins: formation in vitro of heterotypic complexes and intermediate-sized filaments by homologous and heterologous recombinations of purified polypeptides. J Cell Biol. 1985;101:1826–1841.
7. Reichelt J, Bussow H, Grund C, Magin TM. Formation of a normal epidermis supported by increased stability of keratin 5 and 14 in keratin 10 null mice. Mol Biol Cell. 2001;12:1557–1568.
8. Christie M, Chang CW, Rona G, et al. Structural biology and regulation of protein import into the nucleus. J Mol Biol. 2016;428:2060–2090.
9. Melen K, Kinnunen L, Julkunen I. Arginine/lysine-rich structural element is involved in interferon-induced nuclear import of STATs. J Biol Chem. 2001;276:16447–16455.
10. Lim YH, Qiu J, Saraceni C, et al. Genetic reversion via mitotic recombination in ichthyosis with confetti due to a KRT10 polyalanine frameshift mutation. J Invest Dermatol. 2016;136(8):1725–1728.
11. Hotz A, Oji V, Bourrat E, et al. Erratum in: Expanding the clinical and genetic spectrum of KRT1, KRT2 and KRT10 mutations in keratinopathic ichthyosis. Acta dermato-venerologica. 2016;96:720.
12. Fagerlund R, Melen K, Kinnunen L, Julkunen I. Arginine/lysine-rich nuclear localization signals mediate interactions between dimeric STATs and importin alpha 5. J Biol Chem. 2002;277:30072–30078.
13. den Dunnen JT, Dalgleish R, Maglott DR, et al. HGVS recommendations for the description of sequence variants: 2016 update. Hum Mutat. 2016;37:564–569.
14. Hotz A, Oji V, Bourrat E, et al. Expanding the Clinical and Genetic Spectrum of KRT1, KRT2 and KRT10 Mutations in Keratinopathic Ichthyosis. Acta dermato-venerologica. 2016;96:473–478.
15. Richardson ES, Lee JB, Hyde PH, Richard G. A novel mutation and large size polymorphism affecting the V2 domain of keratin 1 in an African-American family with severe, diffuse palmoplantar keratoderma of the ichthyosis hystrix type. J Invest Dermatol. 2006;126:79–84.
16. Sprecher E, Ishida-Yamamoto A, Becker OM, et al. Evidence for novel functions of the keratin tail emerging from a mutation causing ichthyosis hystrix. J Invest Dermatol. 2001;116:511–519.
17. Whittrock NV, Smith FJ, Wan H, et al. Frameshift mutation in the V2 domain of human keratin 1 results in striate palmoplantar keratoderma. J Invest Dermatol. 2002;118:838–844.
18. Aushev M, Koller U, Mussolino C, et al. Traceless targeting and isolation of gene-edited immortalized keratinocytes from epidermolysis bullosa simplex patients. Mol Ther Methods Clin Dev. 2017;6:112–123.

ORCID

Bettina Burger https://orcid.org/0000-0002-7686-0176
